New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
06:15 EDTOMC, ESRX, CMG, EMCOmnicom, Chipotle, EMC sue shareholder activist, WSJ reports
Four firms -- EMC (EMC), Express Scripts (ESRX), Omnicom (OMC) and Chipotle (CMG) -- have sued shareholder activist John Chevedden in recent weeks in a move to block his non-binding proposals from receiving a shareholder vote, the Wall Street Journal reports. Reference Link
News For EMC;ESRX;OMC;CMG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
October 7, 2015
19:22 EDTEMCEMC in merger talks with Dell, WSJ says
Dell and EMC are engaged in merger discussions, reports the Wall Street Journal, citing people familiar with the matter. It is unclear if the companies are considering a partial or full takeover of EMC, the Journal adds. Reference Link
19:11 EDTEMCEMC jumps after hours, levels to watch
Shares were last at $28 on light volume, with next resistance at $28.70. The 52-week high is at $30.92. Support is at $27.64. Dow Jones reported that Dell is in merger talks with EMC.
18:59 EDTEMCDell in merger talks with EMC, Dow Jones reports
Subscribe for More Information
18:21 EDTCMGChipotle initiated with a Buy at SunTrust
Subscribe for More Information
October 6, 2015
18:48 EDTESRXExpress Scripts to include Praluent and Repatha in its formulary
Subscribe for More Information
17:10 EDTESRXAmgen confirms Express Scripts to include Repatha on formulary
Subscribe for More Information
October 5, 2015
10:02 EDTESRXBofa/Merrill healthcare analysts hold an analyst/industry conference call
Subscribe for More Information
October 1, 2015
13:58 EDTESRXExpress Scripts hints at slow start for new cholesterol drugs
An interview with Express Scripts' (ESRX) Everett Neville hinted at slow adoption rates for a pair of new cholesterol treatments known as PCSK9 inhibitors, spurring Piper Jaffray analysts to weigh in on the matter this morning. REJECTION RATES: In a Reuters interview published Wednesday, Express Scripts VP of Pharma Strategies and Chief Trade Relations Officer Everett Neville commented that two new PCSK9 drugs would not be "budget busters" because most prescriptions for the treatments are actually being denied. Praluent from Regeneron (REGN) and Sanofi (SNY) as well as Amgen's (AMGN) Repatha were approved in recent months to treat high cholesterol, but their $14,000-plus yearly costs have come under fire, including from the Institute for Clinical and Economic Review. "We're seeing a lot of patients who either don't qualify or their physicians are not providing [necessary] information," Neville explained, indicating that use of the cholesterol treatments is coming in at the low end of expectations. ANALYST BREAKDOWN: Piper Jaffray analyst Edward Tenthoff said Neville's statements "validate" his view that PCSK9 adoption rates would be vulnerable to pushback from reimbursers like Express Scripts. Tenthoff added that he continues to see a slow launch for Regeneron's Praluent in particular, especially given the lack of cardiovascular outcomes data. Fellow Piper Jaffray analyst Joshua Schimmer took a more optimistic view, acknowledging the apparently high prescription rejection rate but arguing that the patient pool for the drugs is expected to "grow substantially" once cardiovascular data is released. PRICE ACTION: Express Scripts shares have slipped roughly 0.9% amid broader market losses, while shares of Regeneron, Sanofi, and Amgen are all showing minor declines of less than 1%.
13:23 EDTEMCElliott plans to give EMC most of October to respond to demands, Reuters says
Subscribe for More Information
10:50 EDTESRXLeerink healthcare services analyst holds analyst/industry conference call
Analyst Larsen, along with Dan Steiber of D2 Pharma Consulting and James Kenney, Jr., of Harvard Pilgrim Health Care, discuss Hillary Care's potential impact to the Prescription Drug Supply Chain, the impact of the Medicaid rebate program and the uptake of bio-similars and generic launches in 2015 on an Analyst/Industry conference call to be held on October 2 at 12 pm.
05:54 EDTESRXExpress Scripts hinted at slow anti-PCSK9 launches, says Piper Jaffray
Subscribe for More Information
September 30, 2015
17:34 EDTESRXExpress Scripts says many PCSK9 prescriptions denied, Reuters reports
Subscribe for More Information
11:29 EDTEMCAnalyst says key tech trend positive for EMC, negative for IBM
The adoption of platform-as-a-service will accelerate, creating more positive opportunities for EMC (EMC) and posing challenges for IBM (IBM), research firm Jefferies wrote in a note to investors today. WHAT'S NEW: The growth of PaaS will accelerate because the technology enables faster and cheaper development of apps, while the proliferation of mobile apps and the increased digitization of businesses will lead to greater adoption, Jefferies analyst James Kisner stated. PaaS usage will "explode" as companies leverage apps, becoming software makers in some ways, predicted Kisner, who noted that tech research firm IDC expects the number of apps to jump 1000% in three years. EMC's Pivotal business, which enables enterprises to analyze data produced by cloud infrastructure, could be significant as app usage surges, according to Kisner. Conversely, 50% of IBM's profits are generated by middleware that "is likely to be somewhat cannibalized by PaaS," the analyst believes. The Street's revenue estimates for IBM, which call for a decline of 2% in 2016 and little change in 2017, are overly optimistic, according to Kisner, who kept a Buy rating on EMC and an Underperform rating on IBM. PRICE ACTION: In morning trading, EMC rose 2.6% to $23.74 and IBM advanced 2% to $145.34.
10:47 EDTESRXLeerink analyst/industry conference call date/time changed from October 8 10 am
Healthcare Distribution & Technology Larsen, along with Diplomat Pharmacy Chairman & CEO Hagerman and CFO & Secretary/Treasurer Whelan, provide industry insights including the potential impact of Hillary Care, the influence CMS may have on overall drug pricing and recent stock volatility on an Analyst/Industry conference call now being held at a new date and time of September 30 at 5 pm.
09:25 EDTEMCJefferies more positive on EMC, more negative on IBM
Subscribe for More Information
06:12 EDTEMCEMC's Goulden: Breaking off VMware 'wrong thing to do,' Re/code reports
EMC (EMC) president David Goulden said his firm will try to maintain its complex corporate structure amid pressure to spin off its stake in VMware (VMW), Re/code reports. "We believe strongly that breaking up is the wrong thing to do," Goulden said in an interview at Re/code's Code/Enterprise Series event. Reference Link
September 29, 2015
11:38 EDTCMGMcDonald's rises as analysts weigh in on fast food sector
Shares of McDonald's (MCD) rose in morning trading after Credit Suisse upgraded the Big Mac maker to Outperform. Some McDonald's competitors were also active after Telsey Advisory initiated coverage on multiple companies in the quick-serve and fast casual restaurant space. WHAT'S NEW: Credit Suisse analyst Jason West upgraded McDonald's to Outperform and raised his price target on its shares to $112 from $110. West said that more improvements for the company are "forthcoming" even after CEO Steve Easterbrook announced positive operational and financial steps. The analyst added that checks suggest that U.S. same-store sales trends are beginning to turn as a result of operational and menu changes, as well as some new product wins. West said he sees 5%-6% possible upside to current 2016 expectations and views a favorable risk/reward of roughly 2%-3% downside as opposed to 20% upside, even if the turnaround is "fairly modest." NOTABLE INITIATIONS: Separately, Telsey Advisory Group analyst Bob Derrington initiated coverage of several companies in the restaurant sector, stamping Panera (PNRA) with an Outperform rating and a $225 price target. The analyst noted that the company's plan to become a better dining alternative continues to build traction and that same-store sales trends are likely to speed up in 2016 and 2017. Derrington initiated Jack in the Box (JACK) with an Outperform rating and a price target of $95, as he sees it being positioned for strong appreciation in the year ahead based on management's plan to revitalize and differentiate the Jack in the Box brand. The analyst also expects the company to further differentiate, improve the returns, and position its Qdoba brand for quick growth and recycle its franchise cash flow for better shareholder returns. Derrington initiated coverage of Chipotle (CMG) with a Market Perform rating and an $800 price target, saying that despite the firm's positive prospects due to better-than-most-peer same-store sales and revenue growth, the company's margin risk makes him take a more cautious approach to his rating of the stock. The analyst also tagged Buffalo Wild Wings (BWLD) with a Market Perform rating and a $220 price target, noting that the company's strong growth prospects seem to be reflected in its premium valuation. PRICE ACTION: In morning trading, McDonald's shares rose 1.6% to $97.49, Panera shares gained 0.9% to $191, Jack in the Box advanced 1.1% to $78.24, Chipotle added 1% to $715 and Buffalo Wild Wings were 1.3% higher at $195.68.
10:00 EDTCMGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:31 EDTEMCRe/code to hold a discussion
Subscribe for More Information
06:44 EDTCMGChipotle initiated with a Market Perform at Telsey Advisory
Target $800.
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use